Archive for the ‘Interview’ Category

Q&A with MSL Boston’s Meghan Gross

Friday, January 28th, 2011

Meghan Gross recently joined MSLGROUP as senior vice president of the corporate practice in its Boston office. Gross brings 20 years of experience in private sector B2B marketing, helping C-level executives navigate key reputation issues at the intersection of legal affairs, communications and marketing. Time to get to know her a little better. Read on for a Q&A.

Why did you decide to join MSL?
I just completed nearly a decade on the client side, in the legal services industry.  I had always intended to return to the agency side at some point, and MSLGROUP has always been on my short list for my own use and as a referral to lawyers and clients.  At some point, I believe competency is assumed: to get to the pitch, agencies need to do well at messaging, media relations and be proficient at social media.  But MSLGROUP had the right culture and approach, and I knew was a place I really wanted to develop a practice.

(more…)

Posted in Interview, Reputation | No Comments »

Interview: MSLGROUP Chats with Wendy Diller, Elsevier Business Intelligence

Thursday, December 23rd, 2010

Read on for a PR moment with Wendy Diller, Business Bureau Chief, Biopharma Group, Elsevier Business Intelligence – publisher of such publications as The Pink Sheet and INVIVO. Carol Perlman, MSLGROUP chats with Wendy.

CP: As a bureau chief in the Biopharma Group at Elsevier Business Intelligence (formerly FDC-Windhover), you specialize in analyzing and writing about corporate strategy, business development, and commercial issues in the biopharma industry.  Can you provide some insight as to your role, your team and your publications?
WD: I’m an executive editor at Elsevier Business Intelligence. I’m in charge of business coverage for our biopharma publications, The Pink Sheet and The Pink Sheet DAILY, and a writer/editor for our magazine IN VIVO. We’ve got a group of about nine people who write on business issues related to the biopharma industry for our publications.

(more…)

Posted in Biotechnology, Healthcare, Interview | No Comments »

PRWeek Video: Interview with Olivier Fleurot and Jim Tsokanos

Tuesday, November 30th, 2010

PRWeek’s editor-in-chief Steve Barrett talks with Olivier Fleurot, CEO of MSLGROUP, and Jim Tsokanos, President of MSLGROUP Americas, about the newly re-branded MSLGROUP at the recent PRWeek NEXT Conference that MSLGROUP co-sponsored.

Posted in Interview | No Comments »

The CEO Roundtable: Season of Opportunity or Season of Turmoil? (Part 2 of 2)

Tuesday, November 9th, 2010

Today, our MSL Conversations Blog features the final part of Matt Gardner’s CEO Roundtable in which he chats with Rachel King, CEO of GlycoMimetics, Martin Babler, CEO of Talima Therapeutics and Omar Haffar, CEO of Presidio Pharmaceuticals about current industry trends. Find Part 1 here.

Gardner:  The overall atmosphere has been tough.  Recalls, FDA rejections, reform, finance, policy uncertainty.  Do you see our industry actively leading the charge in economic recovery?

Rachel: I think biotech will be a modest contributor to economic growth overall in the short term.  Longer term, I think the industry will be a major factor in growth and innovation.

Omar: I don’t see our industry playing a leading role in the economic recovery.  The biotech industry over the past 30 years has been somewhat peripheral from a direct impact perspective on the macroeconomic picture.  Our industry is immediately and severely impacted by economic downturns, even transient ones, while the slope for a sustained recovery is usually shallow and long.  This is due in part to the time and capital requirements needed to transition to a revenue generating organization, which also makes the prospect of being acquired as the main value driver.

(more…)

Posted in Biotechnology, Healthcare, Interview | 1 Comment »

The CEO Roundtable: Season of Opportunity or Season of Turmoil? (Part 1 of 2)

Monday, November 8th, 2010

Recently, I sat down to talk current events and industry trends with three leading biotech CEOs. In this discussion are Rachel King, CEO of GlycoMimetics, Martin Babler, CEO of Talima Therapeutics, and Omar Haffar, CEO of Presidio Pharmaceuticals.

Gardner: How have capital markets affected your plans for 2010 and 2011?

Rachel: The downturn in the capital markets certainly affects the ability of all biotech companies to raise money.  It has made all VCs more conservative as they work to raise or preserve their own funds, not to mention as they invest. It has thus limited the number of VCs willing to invest in companies at our stage.  This also increases the importance of some of the strategic investors, and it is good to see more of those funds taking active roles as investors.

(more…)

Posted in Healthcare, Interview | 1 Comment »